Histological and biological characteristics of microinvasion in mammary carcinomas ≤ cm in diameter

Pathology International

Volumn 48, Issue 10, 1998, Pages 800-805

  Takasaki, Takashi ^a   Akiba, Suminori ^b   Sagara, Yoshiatu ^a,c   Yoshida, Hiroki ^a,b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c SAGARA HOSPITAL   (Japan)

Author keywords

Basement membrane; Collagen IV; Invasion; Laminin; Mammary carcinoma

Indexed keywords

COLLAGEN TYPE 4; ESTROGEN RECEPTOR; LAMININ; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031669393     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03840.x     Document Type: Article

References (39)

1. Fechner RE, Millis SE, eds. Breast Pathology. ASCP Press, Chicago, 1991.
2. Gallager HS, Martion JE. An orientation to the concept of minimal breast cancer. Cancer 1971; 28: 1505-1507.
3. Wanebo HJ, Huvos AG, Urban JA. Treatment of minimal breast cancer. Cancer 1974; 33: 349-357.
4. Bedwani R, Vana J, Rosner D, Schmitz RL, Murphy GP. Management and survival of female patients with 'minimal' breast cancer: As observed in the long term and short term surveys of the American College of Surgeons. Cancer 1981; 47: 2769-2778.
5. Hartmann WH. Minimal breast cancer. Cancer 1984; 53: 681-684.
6. Sakamoto G, Sugano H, Fukami A, Hori M, Hisano K. Clinicopathological study of minimal breast cancer. Gan no Rinsho 1977; 23: 541-545 (in Japanese).
7. Vecchione A. New and old in prognosis determination in vivo 1993; 7: 623-626.
8. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984; 53: 630-643.
9. Crowe JP, Gordon NH, Hubay CA, Pearson OH, Marshall JS, McGuire WL. The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients. Surgery 1986; 100: 599-605.
10. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 1983; 309: 1343-1347.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
12. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989; 49: 3104-3108.
13. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51: 944-948.
14. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 1991; 63: 434-438.
15. Nagai MA, Marques LA, Torloni H, Brentani MM. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 1993; 50: 412-417.
16. Dawkins HJS, Robbins PD, Smith KL et al. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Pathol. Res. Pract. 1993; 189: 1233-1252.
17. Suzuki M, Okuyama T, Yoshikawa K et al. Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomas. Pathol. Int. 1996; 46: 46-53.
18. Bloom HGJ, Richardson WW. Histologic grading and prognosis in breast cancer. Br. J. Cancer 1957; 11: 655-669.
19. The Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer, 12th edn. Kanehara, Tokyo, 1996.
20. Ohyabu I, Takasaki T, Akiba S et al. Immunohistochemical studies on expression of human vascular smooth-muscle myosin heavy-chain isoforms in normal mammary glands, benign mammary disorders and mammary carcinomas. Pathol. Int. 1998; 48; 433-439.
21. Charppin C, Lissitzky JC. Immunohistochmical detection of laminin in 98 human breast carcinomas: A light and electron microscopic study. Hum. Pathol. 1986; 17: 355-365.
22. Albrechtsen R, Nielsen M. Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. Cancer Res. 1981; 41: 5076-5081.
23. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant disease. Cancer Res. 1982; 42: 4763-4770.
24. Odermatt BF, Lang AB, Ruttner JR, Winterhalter KH, Trueb B. Monoclonal antibodies to human type IV collagen: Useful reagents to demonstrate the heterotrimeric nature of the molecule. Proc. Natl Acad. Sci. USA 1984; 81: 7343-7347.
25. Wewer U, Albrechtsen R, Manthorpe M et al. Human laminin isolated in a nearly intact, biologically active form from placenta by limited proteolysis. J. Biol. Chem. 1983; 258: 12 654-12 660.
26. Engvall E, Davis GE, Dickerson K et al. Mapping of domains in human laminin using monoclonal antibodies: Localization of the neurite-promoting site. J. Cell Biol. 1986; 103: 2457-2465.
27. Moriki T, Takahashi T, Hiroi M et al. Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: An immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. Pathol Int. 1996; 46: 417-425.
28. Moriki T, Takahashi T, Kataoka H et al. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen status. Pathol Int. 1996; 46: 953-961.
29. Fisher EF, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6) I: Intraductal carcinoma (DCIS). Cancer 1986; 57: 197-208.
30. Verhoeven D, Van Marck E. Proliferation, basement membrane changes, metastasis and vascularization patterns in human breast cancer. Pathol. Res. Pract. 1993; 189: 851-861.
31. Noel A, Fontes R, Emonard H, Foidart JM. Extensive deposition of basement membrane by tumors: A prognostic factor? A reappraisal. Epithelial Cell Biol. 1993; 2: 150-154.
32. Wetzels RHW, Holland RE. Detection of basement membrane components and basal cell keration 14 in noninvasion and invasive carcinoma of the breast. Am. J. Pathol. 1989; 134: 571-579.
33. Bosman ET, Havenith M, Cleutjens JPM. Basement membranes in cancer. Ultrastruct. Pathol. 1985; 8: 291-304.
34. Tsuda H. Clinicopathological implications of gene alterations in breast cancer. Jpn. Clin. Pathol. 1993; 41: 1092-1098.
35. Tsuda H, Hirohashi S. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients. Jpn. J. Cancer Res. 1990; 81: 327-332.
36. Tsuda H, Hirohashi S. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1990; 65: 1794-1800.
37. Wright C, Angus B. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
38. Babiak J, Hugh J, Poppema S. Significance of c-erbB-2 amplification and DNA aneuploidy, analysis in 78 patients with node-negative breast cancer. Cancer 1992; 70: 770-776.
39. McCann AH, Dervan PA, O'Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res. 1991; 51: 3296-3303.